Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made significant progress in transition & expand the hereditary cancer market, diversify revenues by commercializing its new products, increase the company's international contribution by investing in large countries, gaining reimbursement for new products, increasing international RNA kit revenue and enhancing profitability. Its flagship product BRACAnalysis offers a comprehensive analysis of BRCA1 and BRCA2 genes to assess a woman's risk of hereditary breast and ovarian cancers. Its major products are myRisk Hereditary Cancer, myPlan Lung Cancer and molecular diagnostic test myPath Melanoma. It acquired Counsyl, Inc. The company has 2 operating units: Molecular diagnostic & Pharmaceutical and clinical services.
| Revenue (Most Recent Fiscal Year) | $837.60M |
| Net Income (Most Recent Fiscal Year) | $-127.30M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.56 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.66 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 5.06 |
| Pre-Tax Margin (Trailing 12 Months) | -15.28% |
| Net Margin (Trailing 12 Months) | -12.20% |
| Return on Equity (Trailing 12 Months) | -4.95% |
| Return on Assets (Trailing 12 Months) | -3.39% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.90 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.08 |
| Inventory Turnover (Trailing 12 Months) | 9.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.70 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.12 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 92.18M |
| Free Float | 89.97M |
| Market Capitalization | $466.42M |
| Average Volume (Last 20 Days) | 1.24M |
| Beta (Past 60 Months) | 1.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.02% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |